• 
  Ingrid Masson, Laurène Larriviere, Marc-André Mahé, David Azria, Pascal Pommier, et al.. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer. Clinical and Translational Radiation Oncology, 2024, 44, pp.100702. ⟨10.1016/j.ctro.2023.100702⟩. ⟨hal-04813716⟩
• 
  Pascal-Alexandre Thomas, Anne-Laure Couderc, David Boulate, Laurent Greillier, Aude Charvet, et al.. Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?. Lung Cancer, 2021, 152, pp.86-93. ⟨10.1016/j.lungcan.2020.12.009⟩. ⟨hal-03526487⟩
• 
  Jean-Emmanuel Kurtz, Xavier Buy, Frédéric Deschamps, Erik Sauleau, Amine Bouhamama, et al.. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. European Journal of Cancer, 2021, 143, pp.78-87. ⟨10.1016/j.ejca.2020.10.035⟩. ⟨hal-03623642⟩
• 
  Elisa Gobbini, Anne Claire Toffart, Maurice Pérol, Jean-Baptiste Assié, Michaël Duruisseaux, et al.. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2020, 21 (5), pp.e497-e510. ⟨10.1016/j.cllc.2020.04.013⟩. ⟨hal-04728622⟩
• 
  Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
• 
  Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, et al.. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Advances, 2023, 7 (14), pp.3735-3738. ⟨10.1182/bloodadvances.2023009911⟩. ⟨hal-04239554⟩
• 
  Francesco Fraioli, Nathalie Albert, Ronald Boellaard, Ilaria Boscolo Galazzo, Matthias Brendel, et al.. Perspectives of the European Association of Nuclear Medicine on the role of artificial intelligence (AI) in molecular brain imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 51 (4), pp.1007-1011. ⟨10.1007/s00259-023-06553-1⟩. ⟨inserm-04783173⟩
• 
  Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, et al.. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. Journal of Clinical Oncology, 2022, 40 (28), pp.3239-3245. ⟨10.1200/JCO.22⟩. ⟨inserm-04783079⟩
• 
  C.S. Groeneveld, C. Pfister, S. Culine, V. Harter, C. Krucker, et al.. Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial. Annals of Oncology, 2024, ⟨10.1016/j.annonc.2024.09.008⟩. ⟨hal-04780573⟩
• 
  V. Camus, R. Houot, G. Brisou, B. Tessoulin, S. Bailly, et al.. Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.. Blood Advances, 2024, 8 (20), pp.5371-5381. ⟨10.1182/bloodadvances.2024013726⟩. ⟨hal-04708799⟩
• 
  Riccardo Rigo, Rabie Chelbi, Julie Agopian, Sebastien Letard, Aurélien Griffon, et al.. TET2 regulates immune tolerance in chronically activated mast cells. JCI Insight, 2022, 7 (7), ⟨10.1172/jci.insight.154191⟩. ⟨hal-04772652⟩
• 
  Olivier Bylicki, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz, et al.. Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial. Lung Cancer, 2024, 194, pp.107866. ⟨10.1016/j.lungcan.2024.107866⟩. ⟨hal-04751314⟩
• 
  Francois Gouin, Audrey Michot, Mehrdad Jafari, Charles Honoré, Jean Camille Mattei, et al.. Improved metastatic-free survival after systematic re-excision following complete macroscopic unplanned excision of limb or trunk soft tissue sarcoma. Cancers, 2024, 16 (7), pp.1365. ⟨10.3390/cancers16071365⟩. ⟨hal-04653665⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. New England Journal of Medicine, 2024, 391 (9), pp.789-799. ⟨10.1056/NEJMoa2403394⟩. ⟨inserm-04761524⟩
• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2023, 29 (10), pp.2665-2665. ⟨10.1038/s41591-023-02624-w⟩. ⟨hal-04755672⟩
• 
  Stéphane J.C. Mancini, Karl Balabanian, Isabelle Corre, Julie Gavard, Gwendal Lazennec, et al.. Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Frontiers in Immunology, 2021, 12, pp.766275. ⟨10.3389/fimmu.2021.766275⟩. ⟨hal-04673450⟩
• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2024, 30 (7), pp.2089 - 2089. ⟨10.1038/s41591-024-03053-z⟩. ⟨hal-04753011⟩
• 
  Nadège Baldeck, Régine Janel-Bintz, Jérome Wagner, Agnès Tissier, Robert Fuchs, et al.. FF_483–484 motif of human Polη mediates its interaction with the POLD2 subunit of Polδ and contributes to DNA damage tolerance. Nucleic Acids Research, 2016, 43 (4), pp.2116-2125. ⟨10.1093/nar/gkv076⟩. ⟨hal-03300649⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Léa Montégut, Peng Liu, Liwei Zhao, María Pérez-Lanzón, Hui Chen, et al.. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. Molecular Cancer, 2024, 23 (1), pp.187. ⟨10.1186/s12943-024-02098-5⟩. ⟨hal-04704596⟩

380

382